This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Ankylosing Spondylitis
and you are
between 18 and 45
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The primary objective of this study is to evaluate the efficacy of safety of etanercept dose reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have achieved a significant clinical response.

Provided treatments

  • Drug: etanercept (Half-Dose)
  • Drug: etanercept (Full-Dose)
  • Drug: Sulfasalazine
  • Drug: Celecoxib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02638896. The sponsor of the trial is Zhixiang Huang and it is looking for 100 volunteers for the current phase.
Official trial title:
Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis